Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma

Authors

Jagoda K Jasielec, University of Chicago
Ravi Vij, Washington University School of Medicine in St. Louis
et al.

Journal

Blood

Publication Date

11-26-2020

Volume

136

Issue

22

First Page

2513

Last Page

2523

Document Type

Open Access Publication

DOI

10.1182/blood.2020007522

Rights and Permissions

Jasielec JK, Kubicki T, Raje N, Vij R, Reece D, Berdeja J, Derman BA, Rosenbaum CA, Richardson P, Gurbuxani S, Major S, Wolfe B, Stefka AT, Stephens L, Tinari KM, Hycner T, Rojek AE, Dytfeld D, Griffith KA, Zimmerman TM, Jakubowiak AJ. Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. Blood. 2020 Nov 26;136(22):2513-2523. doi: 10.1182/blood.2020007522 This research was originally published in Blood Advances. © the American Society of Hematology.

Recommended Citation

Jasielec, Jagoda K; Vij, Ravi; and et al., "Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma." Blood. 136, 22. 2513 - 2523. (2020).
https://digitalcommons.wustl.edu/oa_4/520